Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018

On April 9, 2018 Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported that three abstracts relating to the company’s lead product candidate, tipifarnib, and ERK inhibitor, KO-947, will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018, which will be held from April 14-18, 2018 in Chicago (Press release, Kura Oncology, APR 9, 2018, View Source [SID1234525219]).The following abstracts are now available on the AACR (Free AACR Whitepaper) website at www.aacr.org.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tipifarnib is Highly Active in HRAS Mutant Lung Squamous Carcinoma Tumor
Models (Abstract # 4917)
Session Category: Experimental and Molecular Therapeutics
Session Title: Pharmacokinetics and Pharmacodynamics
Session Date and Time: Tuesday, April 17, 2018, 1:00 p.m. – 5:00 p.m.
Location: McCormick Place South, Exhibit Hall A, Poster Section 41

11q13 Amplification Selects for Sensitivity to the ERK Inhibitor KO-947 in
Squamous Cell Carcinomas (Abstract # 3885)
Session Category: Experimental and Molecular Therapeutics
Session Title: Pharmacogenetics and Pharmacogenomics
Session Date and Time: Tuesday, April 17, 2018, 8:00 a.m. – 12:00 p.m.
Location: McCormick Place South, Exhibit Hall A, Poster Section 37

Preclinical Activity of Tipifarnib in Cutaneous T-cell Lymphoma (Abstract # 1873)
Session Category: Experimental and Molecular Therapeutics
Session Title: Experimental Agents and Combinations for Hematologic Malignancies 2
Session Date and Time: Monday, April 16, 2018, 8:00 a.m. – 12:00 p.m.
Location: McCormick Place South, Exhibit Hall A, Poster Section 38

Following presentation at the meeting, the posters will be available on Kura’s website at www.kuraoncology.com.